K. Fujiwara Et Al. , "ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer," European-Society-for-Medical-Oncology (ESMO) Asia Congress , vol.30, Singapore, Singapore, 2019
Fujiwara, K. Et Al. 2019. ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer. European-Society-for-Medical-Oncology (ESMO) Asia Congress , (Singapore, Singapore).
Fujiwara, K., Vergote, I. B., Sehouli, J., Salutari, V., Zola, P., Madry, R., ... Wenham, R. M.(2019). ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer . European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore
Fujiwara, K. Et Al. "ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer," European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 2019
Fujiwara, K. Et Al. "ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer." European-Society-for-Medical-Oncology (ESMO) Asia Congress , Singapore, Singapore, 2019
Fujiwara, K. Et Al. (2019) . "ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer." European-Society-for-Medical-Oncology (ESMO) Asia Congress , Singapore, Singapore.
@conferencepaper{conferencepaper, author={K. Fujiwara Et Al. }, title={ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer}, congress name={European-Society-for-Medical-Oncology (ESMO) Asia Congress}, city={Singapore}, country={Singapore}, year={2019}}